Kings Point Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Kings Point Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-854	Closed	-$28K	–	370
2017 Q2	$28K	Sell	854 -1,000	-54%	-$31K	0.01%	262
2017 Q1	$59K	Buy	1,854 +1,000	+117%	+$34.1K	0.01%	210
2016 Q4	$31K	Hold	854	–	–	0.01%	231
2016 Q3	$39K	Sell	854 -201	-19%	-$10.5K	0.01%	208
2016 Q2	$53K	Hold	1,055	–	–	0.01%	181
2016 Q1	$56K	Hold	1,055	–	–	0.01%	177
2015 Q4	$69K	Hold	1,055	–	–	0.02%	176
2015 Q3	$60K	Hold	1,055	–	–	0.02%	199
2015 Q2	$62K	Hold	1,055	–	–	0.02%	195
2015 Q1	$66K	Hold	1,055	–	–	0.02%	191
2014 Q4	$61K	Buy	1,055 +201	+24%	+$11.2K	0.02%	186
2014 Q3	$46K	Hold	854	–	–	0.01%	189
2014 Q2	$45K	Hold	854	–	–	0.01%	188
2014 Q1	$45K	Hold	854	–	–	0.01%	181
2013 Q4	$34K	Sell	854 -114	-12%	-$4.49K	0.01%	198
2013 Q3	$37K	Hold	968	–	–	0.01%	195
2013 Q2	$38K	Buy	+968	New	+$37.7K	0.02%	203

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kings Point Capital Management's TEVA Position: Q3 2017 in Review

Kings Point Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 854 shares — an estimated $28K sold.

Kings Point Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $69K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Kings Point Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Kings Point Capital Management sold 854 Teva Pharmaceuticals shares in Q3 2017, an estimated $28K.
Kings Point Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Kings Point Capital Management's Teva Pharmaceuticals position peaked at $69K in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Kings Point Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.